“This clearance represents a significant advance in infectious disease care and the fight to address antibiotic resistance. Our groundbreaking Selux NGP System holds the potential to save lives and decrease over-reliance on broad-spectrum antibiotics, a key factor contributing to the rise of superbugs,” said Steve Lufkin, CEO of Selux Diagnostics.
James S. Lewis II, PharmD, FIDSA, co-director of antibiotic stewardship at Oregon Health and Science University, and chair, CLSI Anti-microbial Susceptibility Testing Subcommittee, said: “We have been waiting for true innovation in AST technologies to deliver rapid results that are accurate according to the latest FDA guidelines and include newly approved antibiotics. I am enthusiastic that the Selux NGP System addresses these critical needs and will become an essential tool for directing personalized therapies for infected patients.”
Experts predict that without a significant change in today’s treatment options, deaths from superbugs will surpass deaths from cancer by 2050. Selux is confronting this global health crisis head-on by redefining the speed and performance of AST, the critical diagnostic test that informs personalized antibiotic therapy.
For more information, visit www.seluxdx.com.
Digital issue: Please click here for more information